- Poster presentation
- Open Access
Urinary tract infection in cancer patients in a tertiary cancer setting in India: microbial spectrum and antibiotic susceptibility pattern
© Parikh and Bhat; licensee BioMed Central Ltd. 2015
- Published: 16 June 2015
- Urinary Tract Infection
- Antimicrobial Susceptibility
- Klebsiella Pneumoniae
In immunocompromised cancer patients, urinary tract infection (UTI) is one of the major causes of fever and morbidity. Screening for UTI is important as atypical presentation is not uncommon in such patients.
To determine the common organisms implicated in UTIs in cancer patients and to study their antimicrobial susceptibility patterns. This would help formulate empirical antibiotic policy in this group of patients.
A retrospective analysis of cancer patients suspected to have UTI in the year 2014 was carried out. A total of 497 midstream urine samples collected from cancer patients suspected to have UTI, were sent to the microbiology lab for urine routine and culture examination. Samples were processed as per standard microbiological procedures. All isolates were identified up to species level and antimicrobial susceptibility tests performed as per CLSI guidelines.
Of the 497 samples processed, 100 were positive for bacterial growth. Overall, E.coli (40%) was the predominant isolate followed by Klebsiella pneumoniae (25%), Pseudomonas aeruginosa (11%), Enterococcus spp (11%) and Proteus mirabilis (5%). Susceptibility of Gram negative bacteria to colistin was highest (100%) followed by the carbapenems (72%). Resistance was found to be higher to the aminoglycosides (46%), cephalosporins (67%) and fluoroquinolones (90%)
E. coli was the most common organism isolated in cancer patients with UTI. There is trend of increasing resistance to aminoglycosides, cephalosporins and fluoroquinolones among Gram negative bacilli.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.